Professor Jürgen Rockstroh at IAS 2023. Photo by Roger Pebody/AidsmapA combination of the non-nucleoside reverse transcriptase inhibitor doravirine and the experimental antiretroviral islatravir proved just as effective as the combination of bictegravir, emtricitabine and tenofovir alafenamide (Biktarvy) in suppressing HIV in previously untreated people after 48 weeks of treatment, Professor Jürgen Rockstroh of the University of Bonn reported at the 12th International AIDS Society Conference on HIV Science (IAS 2023) in Brisbane, Australia.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.